Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Oliver Fairhurst, Claire Gregg, Georgia Jenkins and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor).

InternKats: Wissam Bentazar, Simone Lorenzi and Kliment Markov.
Results for dosage regime patents
Mechanistic insights supporting the sufficiency and inventive step of a therapeutic use (without clinical data) (T 1601/22) Mechanistic insights supporting the sufficiency and inventive step of a therapeutic use (without clinical data) (T 1601/22) Reviewed by Dr Rose Hughes on Friday, January 02, 2026 Rating: 5
The criteria for the novelty and inventive step of pharmaceutical selection inventions (T 1356/21) The criteria for the novelty and inventive step of pharmaceutical selection inventions (T 1356/21) Reviewed by Dr Rose Hughes on Wednesday, December 13, 2023 Rating: 5
BREAKING: Supreme Court confirms no hard line on inventive step test in finding Cialis dosage patent obvious BREAKING: Supreme Court confirms no hard line on inventive step test in finding Cialis dosage patent obvious Reviewed by Dr Rose Hughes on Wednesday, March 27, 2019 Rating: 5
French Supreme Court in Finasteride second-medical use litigation acknowledges patentability of dosage regime claims French Supreme Court in Finasteride second-medical use litigation acknowledges patentability of dosage regime claims Reviewed by Annsley Merelle Ward on Thursday, January 11, 2018 Rating: 5
The rise of "obvious to try" is over as Court of Appeal finds CIALIS dosage regimen patent obvious The rise of "obvious to try" is over as Court of Appeal finds CIALIS dosage regimen patent obvious Reviewed by Annsley Merelle Ward on Sunday, November 05, 2017 Rating: 5
UPDATE: Birss J refuses permission to appeal in Genentech's Herceptin battle UPDATE: Birss J refuses permission to appeal in Genentech's Herceptin battle Reviewed by Annsley Merelle Ward on Friday, May 23, 2014 Rating: 5
Subscribe to: Posts ( Atom )
Powered by Blogger.